Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 13, 2017 (Event Date)
Reporting Period: Specific events occurring on October 13, 2017, and October 17, 2017.
Key Financial Metrics and Agreements
This filing details a material definitive agreement and a capital raising event rather than periodic financial performance metrics (revenue, profit, cash flow).
- License Agreement Upfront Payment: $5.0 million payable to Allergan plc (via Vitae Pharmaceuticals, Inc.).
- Potential Development/Regulatory Milestones: Up to $99 million contingent on achievement of specific events.
- Potential Sales Milestones: Up to $70 million contingent on annual sales thresholds.
- Royalties: Low single to low double-digit percentages on sales of commercialized assets.
- Capital Raise: $25 million registered direct offering of common stock announced October 17, 2017.
Material Changes and Events
Entry into Material Definitive Agreement (Item 1.01): On October 13, 2017, Syndax entered into an exclusive, worldwide, sublicenseable license agreement with Vitae Pharmaceuticals, Inc. (a subsidiary of Allergan plc). The agreement covers a portfolio of preclinical, orally-available small molecule inhibitors targeting the Menin-MLL protein interaction ("Menin Assets"). Syndax assumes sole responsibility for development and commercialization.
Capital Markets Activity (Item 8.01): On October 17, 2017, the Company announced a $25 million registered direct offering of common stock. This event is intended to provide liquidity and support the Company's operations and the newly acquired assets.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The Company intends to develop and commercialize the Menin Assets. The agreement includes termination rights for material breach, insolvency, or at will by the Company (with notice). Allergan retains termination rights if the Company challenges the validity of licensed patents.
Risks and Contingencies:
- Forward-Looking Statements: Actual results may differ due to safety/efficacy data, clinical trial enrollment rates, competition, regulatory changes, or litigation.
- Financial Obligations: Significant contingent liabilities exist in the form of milestone payments ($169 million total potential) and royalties.
- Supplemental Risk Factors: The Company filed supplemental risk factors related to the registered direct offering, which may materially and adversely affect its business and financial condition.
Investor Verification Checklist
- Verify the exact terms of the Menin-MLL license agreement, specifically the definitions of milestone events and royalty reduction circumstances.
- Confirm the final closing details and share count of the $25 million registered direct offering.
- Review the "Supplemental Risk Factor Disclosure" (Exhibit 99.3) for specific risks associated with the capital raise.
- Monitor future filings for the execution of the upfront $5.0 million payment and any initial milestone triggers.
- Assess the Company's cash runway post-offering relative to the development costs of the Menin Assets.